GH Guardant Health
- 18.260
- +0.260+1.44%
- 18.940
- +0.680+3.72%
Guardant Health News
Guardant Health Is Maintained at Buy by Canaccord Genuity
Guardant Health Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Guardant Health, Lowers Price Target to $30
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 to $30.
Express News | Guardant Health Inc : Canaccord Genuity Cuts Target Price to $30 From $45
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Express News | Craig-Hallum Assumes Guardant Health at Buy, Announces Price Target of $28
Express News | Guardant Health, Inc. : Craig-Hallum Cuts Target Price to $28 From $54
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Health care stocks rose Monday afternoon with both the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 1%. The iShares Biotechnology ETF (IBB) climbed 1.7%. In cor
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Matterport, Inc. (NASDAQ:MTTR) rose sharply during Monday's session.CoStar Group, Inc. (NASDAQ:CSGP) anno
Express News | FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will
Guardant Health Is Maintained at Buy by Goldman Sachs
Guardant Health Is Maintained at Buy by Goldman Sachs
Express News | Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $28
Express News | Guardant Health Inc : Leerink Partners Cuts Target Price to $40 From $50
Analyst Expectations For Guardant Health's Future
During the last three months, 5 analysts shared their evaluations of Guardant Health (NASDAQ:GH), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent ratin
Express News | Guggenheim Reiterates Neutral on Guardant Health
Guardant Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 — Guggenheim Reiterates → Neutral 02/26/2024 64.35% Piper Sandler $40 → $30 Maintains Overweig
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal in
20 Foods To Reduce Cancer Risk
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 47% Undervaluation?
Key Insights Guardant Health's estimated fair value is US$39.28 based on 2 Stage Free Cash Flow to Equity Guardant Health's US$20.63 share price signals that it might be 47% undervalued Analyst p
Guardant Health Up Nearly 11%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk
Guardant Health, Inc. (GH) is currently at $19.93, up $1.97 or 10.97% --Would be highest close since Feb. 26, 2024, when it closed at $20.14 --On pace for largest percent increase since May 10, 2023
Analysis
Price Target
No Data
